Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Current Ratio1.42
Quick Ratio1.13
Price-To-Earnings
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales4.48
Price / Cash Flow14.72
Price / Book3.91
Profitability
Net Income$477 million
Net Margins2.91%
Return on Assets6.95%
Miscellaneous
Employees99,000
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, January 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, October, 17th. The healthcare product maker reported $0.75 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.75. The healthcare product maker had revenue of $7.66 billion for the quarter, compared to analysts' expectations of $7.65 billion. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. The company's quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.66 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
How can I listen to Abbott Laboratories' earnings call?
Abbott Laboratories will be holding an earnings conference call on Wednesday, January 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for ABT?
21 Wall Street analysts have issued 12 month price targets for Abbott Laboratories' stock. Their forecasts range from $68.00 to $86.00. On average, they anticipate Abbott Laboratories' stock price to reach $76.8474 in the next year. This suggests a possible upside of 10.1% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Has Abbott Laboratories been receiving favorable news coverage?
Headlines about ABT stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the healthcare product maker a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the next several days.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Retirement Systems of Alabama (0.05%), Park National Corp OH (0.03%), Gofen & Glossberg LLC IL (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which institutional investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Sit Investment Associates Inc., Gulf International Bank UK Ltd, Prentiss Smith & Co. Inc., First Financial Bank Trust Division, Legacy Advisors LLC, First Midwest Bank Trust Division and Greylin Investment Mangement Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which institutional investors are buying Abbott Laboratories stock?
ABT stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Centre Asset Management LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Cullinan Associates Inc., Granite Investment Advisors LLC, Dorsey Wright & Associates, Pennsylvania Trust Co and TrimTabs Asset Management LLC. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $69.82.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $123.77 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
